Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?

Kidney Int. 2007 Dec;72(11):1301-3. doi: 10.1038/sj.ki.5002557.

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease. Novel preventive measures for diabetic renal complications are urgently needed. Miyazaki et al. report that rosiglitazone, a thiazolidinedione insulin sensitizer and a potent peroxisome proliferator-activated receptor gamma agonist, not only effectively improves glycemic control but also halts progression of albuminuria in type 2 diabetic patients with early-stage diabetic nephropathy. These findings could offer a new prevention of diabetic nephropathy in insulin-resistant diabetic patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Albuminuria / etiology
  • Albuminuria / prevention & control
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / prevention & control*
  • Glucose / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • PPAR gamma / agonists
  • Rosiglitazone
  • Thiazolidinediones / therapeutic use*

Substances

  • Hypoglycemic Agents
  • PPAR gamma
  • Thiazolidinediones
  • Rosiglitazone
  • Glucose